A new research perspective was published in , Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of ...

Melanoma, the deadliest form of skin cancer, is often driven by mutations in the BRAF gene, which fuels uncontrolled tumor growth. While BRAF inhibitors (such as vemurafenib) initially halt tumor ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver ...

BRAF will begin moving next month into the lower level of the office building at the corner of Florida and 4th streets, where Chase bank once operated a branch. It will take about four months to ...

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...

standard of care in untreated BRAF V600E-mutant metastatic colorectal cancer. Results showed patients in the encorafenib/cetuximab plus FOLFOX arm had statistically significant improvement in ...

Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.

As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type tumors. We are now investigating the biochemical actions and anti-tumor ...